Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management
Yeon Hee Park, Soo Chin Lee, Christian F. Singer, Judith Balmaña, Rebecca Alexandra Dent, Veronique Kiak-Mien Tan, Nadia Ayu Mulansari, Mastura Md. Yusof, Frances Victoria F. Que, Yen-Shen Lu, Napa Parinyanitikul, Cam Phuong Pham, Nur Aishah Taib, Sun-Young Kong, Yoland Antill
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBRCA gene mutations in cancer · PARP inhibition in cancer therapy · Breast Cancer Treatment Studies
In the published article, there was a mistake in the text and citation in Section 4.4. “HER2-negative metastatic BC carrying BRCA germline pathogenic variant”. In paragraph 1 of the section 4.4, the following text and citation was incorrect “The phase III OlympiAD trial confirmed the effectiveness of olaparib in individuals with hereditary BRCA germline pathogenic variants and HER2-negative mBC, with a statistically significant improvement in progression-free survival and OS compared with the physician’s choice of CT treatment (Table 4) (48). The 4-year OS in the olaparib group was 89·8% compared with 86·4% in the placebo group (9).”
The correct text and citation should be:
“The phase III OlympiAD trial confirmed the effectiveness of olaparib in individuals with hereditary BRCA germline pathogenic variants and HER2-negative mBC, with a statistically significant improvement in progression-free survival compared with the physician’s choice of CT treatment (Table 4) (46). The median final OS was 19.3 months with olaparib and 17.1 months with the physician’s choice of CT, which was comparable between the two groups (48).”
The original version of this article has been updated.